QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Co. stock logo
APYX
Apyx Medical
$1.39
+0.7%
$1.87
$1.21
$7.97
$48.15M1.09150,177 shs26,701 shs
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$0.80
-8.0%
$0.96
$0.80
$4.29
$43.31M0.58161,533 shs153,697 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$1.87
-2.1%
$2.19
$1.60
$9.36
$17.15M0.8668,439 shs20,894 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$18.42
-2.9%
$17.73
$14.51
$22.99
$64.65M0.68,146 shs4,485 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Co. stock logo
APYX
Apyx Medical
-5.48%-5.48%-22.91%-30.30%-54.00%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-0.60%-9.92%-1.50%-14.18%-72.39%
PAVmed Inc. stock logo
PAVM
PAVmed
-1.04%-11.16%0.00%-32.98%-71.06%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
+5.14%+4.74%+10.60%-9.68%+16.37%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Co. stock logo
APYX
Apyx Medical
4.3597 of 5 stars
3.54.00.04.23.31.70.6
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.3294 of 5 stars
3.32.00.00.03.10.00.6
PAVmed Inc. stock logo
PAVM
PAVmed
1.9855 of 5 stars
3.00.00.04.33.90.80.0
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Co. stock logo
APYX
Apyx Medical
3.00
Buy$6.17343.65% Upside
Cytosorbents Co. stock logo
CTSO
Cytosorbents
2.50
Moderate Buy$2.50213.40% Upside
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.001,022.99% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/A

Current Analyst Ratings

Latest CTSO, APYX, PDEX, and PAVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Cytosorbents Co. stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Co. stock logo
APYX
Apyx Medical
$52.35M0.92N/AN/A$0.78 per share1.78
Cytosorbents Co. stock logo
CTSO
Cytosorbents
$36.35M1.19N/AN/A$0.52 per share1.53
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M7.00N/AN/A($3.35) per share-0.56
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$46.09M1.40$2.29 per share8.05$8.91 per share2.07

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$18.71M-$0.54N/AN/AN/A-35.75%-54.90%-28.41%5/9/2024 (Estimated)
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$28.51M-$0.64N/AN/AN/A-78.43%-120.24%-54.11%5/7/2024 (Estimated)
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$7.07M$0.7524.56N/A5.59%8.97%5.40%5/2/2024 (Estimated)

Latest CTSO, APYX, PDEX, and PAVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Apyx Medical Co. stock logo
APYX
Apyx Medical
-$0.13-$0.19-$0.06-$0.10$14.40 million$14.66 million
3/14/2024Q4 2023
Cytosorbents Co. stock logo
CTSO
Cytosorbents
-$0.14-$0.12+$0.02-$0.12$9.29 million$8.67 million
2/8/2024Q2 2024
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/A$0.14+$0.14$0.14N/A$12.59 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Co. stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Cytosorbents Co. stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Co. stock logo
APYX
Apyx Medical
1.23
5.52
4.74
Cytosorbents Co. stock logo
CTSO
Cytosorbents
0.11
1.77
1.51
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.26
3.66
2.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
55.33%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
32.87%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%

Insider Ownership

CompanyInsider Ownership
Apyx Medical Co. stock logo
APYX
Apyx Medical
13.10%
Cytosorbents Co. stock logo
CTSO
Cytosorbents
8.10%
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
42.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Co. stock logo
APYX
Apyx Medical
25234.64 million30.11 millionOptionable
Cytosorbents Co. stock logo
CTSO
Cytosorbents
18654.29 million49.90 millionOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
1249.17 million8.02 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1453.51 million2.02 millionNot Optionable

CTSO, APYX, PDEX, and PAVM Headlines

SourceHeadline
Pro-Dex, Inc. (NASDAQ:PDEX) Sees Significant Decrease in Short InterestPro-Dex, Inc. (NASDAQ:PDEX) Sees Significant Decrease in Short Interest
marketbeat.com - April 13 at 11:20 AM
Pro-Dex (NASDAQ:PDEX) Shares Pass Above 200 Day Moving Average of $17.72Pro-Dex (NASDAQ:PDEX) Shares Pass Above 200 Day Moving Average of $17.72
americanbankingnews.com - April 11 at 3:16 AM
Pro-Dex (NASDAQ:PDEX) Shares Pass Above 200-Day Moving Average of $17.72Pro-Dex (NASDAQ:PDEX) Shares Pass Above 200-Day Moving Average of $17.72
marketbeat.com - April 11 at 3:14 AM
AutoPro X accessory will bring Samsung DeX to your vehicleAutoPro X accessory will bring Samsung DeX to your vehicle
msn.com - April 9 at 10:27 AM
Vicarious Surgical Stock (NYSE:RBOT), Quotes and News SummaryVicarious Surgical Stock (NYSE:RBOT), Quotes and News Summary
benzinga.com - April 2 at 10:06 PM
Monogram Orthopaedics reports FY resultsMonogram Orthopaedics reports FY results
seekingalpha.com - March 15 at 3:03 PM
The Returns On Capital At Pro-Dex (NASDAQ:PDEX) Dont Inspire ConfidenceThe Returns On Capital At Pro-Dex (NASDAQ:PDEX) Don't Inspire Confidence
finance.yahoo.com - February 22 at 2:16 PM
Pro-Dex, Inc. Announces Fiscal 2024 Second Quarter and Six-Month ResultsPro-Dex, Inc. Announces Fiscal 2024 Second Quarter and Six-Month Results
finance.yahoo.com - February 8 at 7:45 PM
Pro-Dex (NASDAQ:PDEX) shareholders have earned a 7.2% CAGR over the last five yearsPro-Dex (NASDAQ:PDEX) shareholders have earned a 7.2% CAGR over the last five years
finance.yahoo.com - January 26 at 7:04 PM
Is Pro-Dex, Inc.s (NASDAQ:PDEX) Latest Stock Performance A Reflection Of Its Financial Health?Is Pro-Dex, Inc.'s (NASDAQ:PDEX) Latest Stock Performance A Reflection Of Its Financial Health?
finance.yahoo.com - December 30 at 4:00 PM
Dex Carvey Dies: Comedian Son Of Dana Carvey Was 32Dex Carvey Dies: Comedian Son Of Dana Carvey Was 32
deadline.com - November 22 at 4:30 AM
PowerDEX Launches: CEX Performance Meets DEX FreedomPowerDEX Launches: CEX Performance Meets DEX Freedom
coinspeaker.com - November 21 at 4:16 PM
Here’s Why You Should Consider Buying Pro-Dex (PDEX) SharesHere’s Why You Should Consider Buying Pro-Dex (PDEX) Shares
finance.yahoo.com - November 14 at 2:04 AM
Pro-Dex Inc PDEXPro-Dex Inc PDEX
morningstar.com - November 10 at 12:39 PM
Pro-Dex, Inc. Announces Fiscal 2024 First Quarter ResultsPro-Dex, Inc. Announces Fiscal 2024 First Quarter Results
finance.yahoo.com - November 2 at 6:52 PM
Pro-Dex Inc (PDEX) Reports 8% Increase in Q1 Fiscal 2024 Net Sales, Despite Net Loss of $615,000Pro-Dex Inc (PDEX) Reports 8% Increase in Q1 Fiscal 2024 Net Sales, Despite Net Loss of $615,000
finance.yahoo.com - November 2 at 6:52 PM
Stock Day Media: Pro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day PodcastStock Day Media: Pro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day Podcast
finanznachrichten.de - October 26 at 10:18 AM
Pro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day PodcastPro-Dex, Inc. Discusses 4th Quarter and Year-End Results with The Stock Day Podcast
finance.yahoo.com - October 26 at 10:18 AM
Pro-Dex Inc (PDEX) Reports Fiscal 2023 Fourth Quarter and Full-Year ResultsPro-Dex Inc (PDEX) Reports Fiscal 2023 Fourth Quarter and Full-Year Results
finance.yahoo.com - October 15 at 12:00 AM
Pro-Dex, Inc. Announces Fiscal 2023 Fourth Quarter and Full-Year ResultsPro-Dex, Inc. Announces Fiscal 2023 Fourth Quarter and Full-Year Results
finance.yahoo.com - October 13 at 7:19 PM
North American Morning Briefing: S&P 500 Futures -2-North American Morning Briefing: S&P 500 Futures -2-
morningstar.com - October 4 at 8:12 AM
Pro-Dexs (NASDAQ:PDEX) Returns Have Hit A WallPro-Dex's (NASDAQ:PDEX) Returns Have Hit A Wall
finance.yahoo.com - August 7 at 7:33 AM
At US$18.26, Is It Time To Put Pro-Dex, Inc. (NASDAQ:PDEX) On Your Watch List?At US$18.26, Is It Time To Put Pro-Dex, Inc. (NASDAQ:PDEX) On Your Watch List?
finance.yahoo.com - June 29 at 1:37 PM
Stock Day Media: Pro-Dex, Inc. Discusses Record 3rd Quarter Results with The Stock Day PodcastStock Day Media: Pro-Dex, Inc. Discusses Record 3rd Quarter Results with The Stock Day Podcast
finanznachrichten.de - June 5 at 12:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apyx Medical logo

Apyx Medical

NASDAQ:APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Cytosorbents logo

Cytosorbents

NASDAQ:CTSO
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Pro-Dex logo

Pro-Dex

NASDAQ:PDEX
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.